TheraRadar
← Back
Data updated: May 24, 2026

THERATECHNOLOGIES

Biotech

THERATECHNOLOGIES is a biotechnology company focused on Infectious Disease, Immunology, Respiratory. Key products include Egrifta WR.

2010
Since
3
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Biologics
Novel Drugs (2018):
1 Novel Approvals 1 First-in-Class 1 Orphan Drug 1 Breakthrough

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Infectious Disease 44%
1 drugs Phase 1: 2
Immunology 33%
1 drugs
Respiratory 11%
0 drugs Phase 2: 1
Oncology 6%
0 drugs Phase 1: 1
Metabolic 6%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
1
Phase 2
4
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • TROGARZO leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling